Not exact matches
This drug (vedolizumab) blocks a specific adhesion molecule on the surface of the T - cell and thereby
inhibits immune cells from binding themselves to
receptors present in the intestine, preventing the T - cells from penetrating the blood vessels in the intestinal tissue.
The
receptor is believed to
inhibit the ability of
immune cells to autodestruct when they have outlived their usefulness, resulting in higher concentrations of proinflammatory signals (such as TNF) in the intestines of IBD patients.
And when they pre-treated
immune cells from vaccinated major allele carriers with a molecule that
inhibits the
receptor that is normally stimulated by IL - 28B, they saw a stronger antibody response after the cells were stimulated with influenza vaccine.
They identified the LPA5
receptor as the specific
receptor responsible for
inhibiting the
immune response.
The rationale for using CT - 011, an immunotherapy antibody that blocks the programmed death (PD)-1
receptor, is to boost the function of the
immune system by
inhibiting PD - 1 whose function, in part, is to
inhibit T - cell response.
Gosselies, Belgium - April 3, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, will present preclinical data for its A2A
receptor antagonist, which
inhibits the
immune suppressive function of adenosine, at the American Association for Cancer Research (AACR) Annual Meeting.
The adenosine A2A
receptor is the main adenosine
receptor expressed on
immune cells, which promote anti-tumor
immune responses, leading to tumor regression when
inhibited with an adenosine A2A antagonist.
Low - dose chemotherapy, radiation, or targeted therapies given in combination with
immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first
immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4)
receptor inhibited T cell responses.
The
immune system mast cells in your intestines and bowels are lined with vitamin D
receptors, and by binding to them vitamin D can
inhibit the release of inflammatory chemicals responsible for the symptoms of bloating, cramps, and abdominal pain.